Skip to main content
Atrás
Watch Compare

Mereo BioPharma Group plc

Calidad de datos: 100%
MREO
NASDAQ Manufacturing Chemicals
$0.33
▲ $0.01 (2.19%)
Cap. Mercado: 50.74 M
6 months return
—
Momentum
Neutral
ROE
-83.11%

Quick Summary

Key Takeaways

Short bullets derived from reported financials—not the AI summary above.

Negative free cash flow of -30.99 M
Capital efficient — spends only 4.00% of revenue on capex

Price History

Crecimiento

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-83.11%
Below sector avg (-54.44%)
ROIC-61.73%
Net Margin-8375.60%
Op. Margin-8021.40%

Seguridad

Debt / Equity
N/A
Current Ratio8.71
Interest Coverage-157.28

Valoración

PE (TTM|NTM)
-1.21 | -11.06
Above sector avg (-1.49)
P/B Ratio1.09
EV/EBITDAN/A
Dividend YieldN/A

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1385 pares)
Métrica Acción Mediana del Sector
P/E -1.2 -1.5
P/B 1.1 1.6
ROE % -83.1 -54.4
Net Margin % -8375.6 -41.5
Rev Growth 5Y % — 1.7
D/E — 0.3

Precio Objetivo de Analistas

6 analistas

Consenso de analistas: objetivo medio vs precio actual y calificación.

Buy
Actual
$0.33
+437.5%
Objetivo
$1.76
$0.50
$1.51
$3.01
Pronóstico
P/E Futuro -11.06
EPS Futuro -$0.03
Ingresos Est. 17.14 M

Estimaciones de Ganancias

Pronósticos de EPS e ingresos por período. Anual = años fiscales; trimestral = próximos trimestres.

Período EPS Est. Ingresos Est. Analistas
FY2027 -$0.03
-$0.05 – $0.01
17.14 M 4
FY2026 -$0.03
-$0.05 – $0.02
9.86 M 5

Sorpresas de Ganancias

Últimos 4 trimestres
Trimestre EPS Est. EPS Real Sorpresa
Q42025 -$0.01 -$0.01 -7.1%
Q32025 $0.00 -$0.01 -117.1%
Q22025 -$0.01 -$0.01 -65.8%
Q12025 -$0.01 -$0.02 -37.6%

ETFs Holding This Stock

BBC logo BBC Virtus Biotech Clinical Trials ETF
0.49% weight
CANC logo CANC Tema Oncology ETF
0.47% weight

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) -77.64%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 500,000.0 Net Income (TTM) -41.88 M
ROE -83.11% ROA -72.06%
Gross Margin N/A Operating Margin -8021.40%
Net Margin -8375.60% Free Cash Flow (TTM) -30.99 M
ROIC -61.73% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 8.71
Interest Coverage -157.28 Asset Turnover 0.01
Working Capital 46.39 M Tangible Book Value 45.96 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1.21 Forward P/E -11.06
P/B Ratio 1.09 P/S Ratio 101.48
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S 2.96 Fwd Earnings Yield N/A
FCF Yield -61.08%
Market Cap 50.74 M Enterprise Value 2.04 M
Per Share
EPS (Diluted TTM) -0.05 Revenue / Share 0.00
FCF / Share -0.19 OCF / Share -0.19
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 4.00% FCF Conversion 74.00%
SBC-Adj. FCF -39.10 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023
Revenue 500,000.0 0.0 10.00 M
Net Income -41.88 M -43.25 M -29.47 M
EPS (Diluted) -0.05 -0.06 -0.04
Gross Profit — — —
Operating Income -40.11 M -47.36 M -28.42 M
EBITDA — — —
R&D Expenses 17.77 M 20.93 M 17.42 M
SG&A Expenses — — —
D&A — — —
Interest Expense 255,000.0 1.37 M 2.88 M
Income Tax 0.0 0.0 -532,000.0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023
Total Assets 45.92 M 76.39 M 66.50 M
Total Liabilities 5.00 M 15.42 M 15.96 M
Shareholders' Equity 40.92 M 60.97 M 50.54 M
Total Debt — — —
Cash & Equivalents 40.99 M 69.80 M 57.42 M
Current Assets 45.02 M 74.76 M 63.76 M
Current Liabilities 4.30 M 13.85 M 9.49 M